



# Pharmacist-Prescribed Paxlovid Guide

The purpose of this document is to serve as a guide for pharmacist - prescribed paxlovid based on the paxlovid FDA EUA. Refer to FDA materials for the most up-to-date information for counseling points and the most comprehensive information.

Pg. 1-3: Pathway

Pg. 4: Checklist for individual patient

Pgs. 5-8: Drug interactions

Pg. 8: Resources

A special thanks to CPESN Pharmacies, Eric's Rx Shoppe and Moose Pharmacy, in PA and NC, respectively, for their contributions to this guide.

# Pharmacist-Prescribed Paxlovid Assessment and Treatment Care Pathway

## Part 1. Review Medical History

<b>Age</b>	Age ≥18 years OR >12 years of age and weighing at least 40kg (88 lb) <b>Continue to next step.</b>	< 18 years/old OR > 12 and weighs less than 40 kg, <b>STOP</b>
<b>Positive COVID-19 Test</b>	If patient has a positive rapid antigen test or a positive PCR test in the last 5 days <b>Continue to next step.</b>	If patient has tested positive > 5 days ago, <b>STOP</b> and consider referring patient for other therapy. <b>Therapeutics Locator:</b> Click <a href="#">here</a> .
<b>Evaluate Patient's Symptoms</b>	If patient has mild-to-moderate symptoms that started in the last 5 days <b>Continue to next step.</b>	If patient started experiencing symptoms over 5 days ago, <b>STOP</b>
Document date of symptom onset	<b><i>If patient is experiencing any of the following symptoms, <u>STOP</u> and refer them to emergency department:</i></b> <ul style="list-style-type: none"> <li><input type="checkbox"/> Shortness of breath or difficulty breathing +/- while at rest</li> <li><input type="checkbox"/> Increasing severity of cough +/- low oxygen levels</li> <li><input type="checkbox"/> Chest or upper abdominal pain/pressure</li> <li><input type="checkbox"/> Sudden dizziness, weakness or fainting</li> <li><input type="checkbox"/> Sudden change in vision</li> <li><input type="checkbox"/> Confusion, sudden change in your mental status, difficulty speaking</li> <li><input type="checkbox"/> Sudden or severe pain</li> <li><input type="checkbox"/> Severe vomiting or diarrhea</li> <li><input type="checkbox"/> Vomiting or coughing blood</li> <li><input type="checkbox"/> Extreme sleepiness or inability to wake</li> <li><input type="checkbox"/> Blue face or lips</li> </ul>	
<b>High-Risk Criteria</b>	If patient meets any of the following, <b>continue to next step:</b> <ul style="list-style-type: none"> <li><input type="checkbox"/> Age over 50, with risk increasing substantially risk ≥ 65 years old</li> <li><input type="checkbox"/> Being unvaccinated or not being up to date on COVID-19 vaccinations</li> <li><input type="checkbox"/> Race or ethnicity other than non-Hispanic white individual</li> <li><input type="checkbox"/> BMI ≥ 25 kg/m<sup>2</sup></li> <li><input type="checkbox"/> Asthma or chronic lung disease (e.g., COPD)</li> <li><input type="checkbox"/> Cancer</li> <li><input type="checkbox"/> Diabetes</li> <li><input type="checkbox"/> Heart conditions</li> <li><input type="checkbox"/> HIV</li> <li><input type="checkbox"/> Sickle cell disease</li> <li><input type="checkbox"/> Pregnancy or recent pregnancy</li> <li><input type="checkbox"/> Primary immunodeficiency or use of immunosuppressant</li> <li><input type="checkbox"/> Smoking, current or former</li> <li><input type="checkbox"/> Liver Disease**</li> <li><input type="checkbox"/> Kidney Disease**</li> <li><input type="checkbox"/> Other: _____</li> </ul>	If patient is not high-risk for progressing to moderate-to-severe COVID-19 illness, <b>STOP</b>
For a full list of risk factors that qualify, click <a href="#">here</a> .		

\*\*Extra caution warranted.

## Part 2. Obtain Pertinent Lab Values from the Last 12 months

- Ask patient if they have access to provider portal or recent labs. Reach out to provider's office for kidney function, along with updated list of medications if needed.

<b>Renal Function eGFR</b>	If patient's eGFR is > 60 mL/min, <b>continue to next step.</b>	If patient's eGFR is 30-59 mL/min, requires dose adjustment and <b>continue to next step.</b>	If patient's eGFR is < 30, <b>STOP</b>
<b>Hepatic Function</b>	Utilize <a href="https://www.mdcalc.com/calc/340/child-pugh-score-cirrhosis-mortality">https://www.mdcalc.com/calc/340/child-pugh-score-cirrhosis-mortality</a> to calculate the patient's Child-Pugh score.		
	If Child-Pugh Score is A or B, <b>continue to next step.</b>	If there are no lab values within the last 12 months to use in the calculator, you may call the patient's PCP to get an assessment of the patient's hepatic function.	If Child-Pugh Score is C, <b>STOP.</b>  Consider referring patient to PCP or other local provider who can provide alternative treatments (e.g., MAB)
<b>Review Hypersensitivity Reactions</b>	No history of clinically significant hypersensitivity reactions [e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome] to the active ingredients (nirmatrelvir or ritonavir) or other components of the product. <b>Continue to next step.</b>	Has a present history of clinically significant hypersensitivity reactions [e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome] to the active ingredients (nirmatrelvir or ritonavir) or other components of the product. <b>STOP</b>	

## Part 3. Obtain Complete Medication List from Patient or Primary Care Provider (or primary pharmacy)

- Ensure a **thorough** and **complete** medication list is obtained, including all prescription, OTC, and herbal supplements.

<b>Medication Review</b>	If the patient is NOT taking any of the medications below or those listed on pages 5-8 and all other medications have been checked for interactions and contraindications*, <b>continue to next step.</b>	If the patient is taking any medications that causes a possible interaction, call the prescriber / PCP to determine if dose modification is needed for other medication and make referral to authorized non-pharmacist prescriber. <b>If dose modification is not needed, may continue to next step.</b>	If other medication requires dose modification, <b>STOP</b>
COVID-19 Drug Interaction Resource: Click <a href="#">here</a> .	*All medications should be reviewed for possible interactions as this is a guide and not comprehensive		Refer patient for clinical evaluation (e.g., telehealth, in-person visit) with a physician, APRN, or PA to prescribe drugs, if modification of other medications is needed due to a potential drug interaction.
The following medications are <b>contraindicated</b> when taking Paxlovid: alfuzosin, amiodarone, apalutamide, carbamazepine, clozapine, colchicine, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, finerenone, flecainide, flibanserin, ivabradine, lomitapide, lovastatin, lumacaftor/ivacaftor, lurasidone, methylergonovine, midazolam (oral), naloxegol, pethidine, phenobarbital, phenytoin, pimozide, piroxicam, primidone, propafenone, quinidine, ranolazine, rifampin, sildenafil (Revatio®) – when used for pulmonary arterial hypertension, silodosin, simvastatin, St. John’s Wort, tolvaptan, triazolam, ubrogepant, voclosporin.			

**Part 4: Determine appropriate paxlovid dosing based on clinical information obtained.**

Choose the appropriate dose	Nirmatrelvir 300 mg/ritonavir 100 mg (3 tablets) twice daily for 5 days	*if eGFR is 30-59, nirmatrelvir 150 mg/ritonavir 100 mg (2 tablets) twice daily for 5 days
-----------------------------	---	--

**Part 5: Scan all documents into pharmacy system for future reference.**

**Part 6: Once criteria is met, make sure patient receives their prescription within a timely manner (offer delivery or curbside pickup).**

- *Consider offering delivery or curbside pickup*

The state-licensed pharmacist should refer an individual patient for clinical evaluation (e.g., telehealth, in-person visit) with a physician, advanced practice registered nurse, or physician assistant licensed or authorized under state law to prescribe drugs, if any of the following apply:

- ☐ Sufficient information is not available to assess renal and hepatic function.
- ☐ Sufficient information is not available to assess for a potential drug interaction.
- ☐ Modification of other medications is needed due to a potential drug interaction.
- ☐ PAXLOVID is not an appropriate therapeutic option based on the authorized [Fact Sheet for Healthcare Providers](#) or due to potential drug interactions for which recommended monitoring would not be feasible.

## Checklist for Pharmacist-Prescribing for Paxlovid

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Weight: \_\_\_\_\_

Date of Assessment: \_\_\_\_\_

☐ Positive Test Documented

☐ Symptoms started in the last 5 days

○ Date of Symptoms: \_\_\_\_\_

☐ Meets high-risk criteria

☐ Age over 50, with risk increasing substantially risk  $\geq 65$  years old

☐ Being unvaccinated or not being up to date on COVID-19 vaccinations

☐ Race or ethnicity other than non-Hispanic white individual

☐ BMI  $\geq 25$  kg/m<sup>2</sup>

☐ Asthma or chronic lung disease (e.g., COPD)

☐ Cancer

☐ Diabetes

☐ Heart conditions

☐ HIV

☐ Sickle cell disease

☐ Pregnancy or recent pregnancy

☐ Primary immunodeficiency or use of immunosuppressant

☐ Smoking, current or former

☐ Liver Disease\*\* (extra caution)

☐ Kidney Disease\*\* (extra caution)

☐ Other: \_\_\_\_\_

☐ No history of clinically significant hypersensitivity reactions

☐ No known or suspected severe renal impairment. eGFR  $> 60$  mL/min or eGFR is 30-59 mL/min

○ If eGFR is 30-59 mL/min, nirmatrelvir 150 mg/ritonavir 100 mg (2 tablets) twice daily for 5 days

☐ No known or suspected severe hepatic impairment. Hepatic Function is classified as Child-Pugh Score of A or B

☐ Access to labs that are within the last 12 months (patient access to provider portal, printed labs, obtained by PCP/provider)

☐ Access to current and complete medication list.

☐ Complete Medication List Reviewed for interactions. No modifications to current drugs needed.

☐ All information received, reviewed, and best course of action decided for the patient.

☐ Scan all documents (positive test, kidney function, other medications) into your pharmacy system under the prescription for future reference.

☐ Produce prescription and dispense paxlovid with appropriate dosage.

**R<sub>x</sub>**

☐ Nirmatrelvir 300 mg/ritonavir 100 mg  
Take 3 tablets PO BID for 5 days  
#30

☐ Nirmatrelvir 150 mg/ritonavir 100 mg  
**(Renal Dose Adjustment)**  
Take 2 tablets PO BID for 5 days  
#20

Pharmacist: \_\_\_\_\_

# PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

## Other Drugs with Established and Other Potentially Significant Drug Interactions with PAXLOVID (listed alphabetically by generic name)

### Interaction Codes:

XXX

Coadministration of this drug with PAXLOVID is CONTRAINDICATED. For further information, refer to the Fact Sheet for Healthcare Providers and the individual Prescribing Information for the drug.

\*\*\*

Coadministration of this drug with PAXLOVID should be avoided and/or holding of this drug, dose adjustment of this drug, or special monitoring is necessary. Consultation with the prescriber of the potentially interacting drug is recommended. For further information, refer to the Health Care Provider Fact Sheet and the individual Prescribing Information for the drug.

*The table below provides a listing of clinically significant drug interactions, including contraindicated drugs, in addition to those listed under Concomitant Medications above (HMG-CoA reductase inhibitors [statins], hormonal contraceptives containing ethinyl estradiol, and medications for HIV-1 treatment). **Drugs listed in this table are a guide and are not considered a comprehensive list of all possible drugs that may interact with PAXLOVID. The healthcare provider should consult other appropriate resources such as the prescribing information for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor such as ritonavir.***

Drug	Drug Class	Interaction Code
abemaciclib	Anticancer drug	***
alfuzosin	Alpha 1-adrenoreceptor antagonist	XXX
aliskiren	Cardiovascular agent	***
amiodarone	Antiarrhythmic	XXX
amlodipine	Calcium channel blocker	***
apalutamide	Anticancer drug	XXX
avanafil	PDE5 inhibitor	***
bedaquiline	Antimycobacterial	***
betamethasone	Systemic corticosteroid	***
bosentan	Endothelin receptor antagonist	***
budesonide	Systemic corticosteroid	***
bupropion	Antidepressant	***
carbamazepine	Anticonvulsant	XXX
ceritinib	Anticancer drug	***



Drug	Drug Class	Interaction Code
ciclesonide	Systemic corticosteroid	***
clarithromycin	Anti-infective	***
clopidogrel	Cardiovascular agent	***
clozapine	Antipsychotic	XXX
colchicine	Anti-gout	XXX
cyclosporine	Immunosuppressant	***
dabigatran	Anticoagulants	***
dasabuvir	Hepatitis C direct acting antiviral	***
dasatinib	Anticancer drug	***
dexamethasone	Systemic corticosteroid	***
digoxin	Cardiac glycoside	***
dihydroergotamine	Ergot derivative	XXX
diltiazem	Calcium channel blocker	***
dronedarone	Antiarrhythmic	XXX
elbasvir/grazoprevir	Hepatitis C direct acting antiviral	***
eletriptan	Migraine medication	XXX
elexacaftor/tezacaftor/ivacaftor	Cystic fibrosis transmembrane conductance regulator potentiator	***
encorafenib	Anticancer drug	***
epiorenone	Cardiovascular agent	XXX
ergotamine	Ergot derivative	XXX
erythromycin	Anti-infective	***
everolimus	Immunosuppressant	***
felodipine	Calcium channel blocker	***
fentanyl	Narcotic analgesic	***
finerenone	Mineralocorticoid receptor antagonist	XXX
flecainide	Antiarrhythmic	XXX
fluticasone	Systemic corticosteroid	***
flibanserin	Serotonin receptor 1A agonist/ serotonin receptor 2A antagonist	XXX
glecaprevir/pibrentasvir	Hepatitis C direct acting antiviral	***
hydrocodone	Narcotic analgesic	***
ibrutinib	Anticancer drug	***
isavuconazonium sulfate	Antifungal	***
itraconazole	Antifungal	***
ivabradine	Cardiovascular agent	XXX
ivacaftor	Cystic fibrosis transmembrane conductance regulator potentiator	***
ivosidenib	Anticancer drug	***
ketoconazole	Antifungal	***

Drug	Drug Class	Interaction Code
lidocaine (systemic)	Antiarrhythmic	***
lomitapide	Microsomal triglyceride transfer protein (MTTP) inhibitor	XXX
lumacaftor/ivacaftor	Cystic fibrosis transmembrane conductance regulator potentiator	XXX
lurasidone	Antipsychotic	XXX
methadone	Narcotic analgesic	***
methylergonovine	Ergot derivative	XXX
methylprednisolone	Systemic corticosteroid	***
midazolam (administered parentally)	Sedative/hypnotic	***
midazolam (oral)	Sedative/hypnotic	XXX
mometasone	Systemic corticosteroid	***
naloxegol	Opioid antagonist	XXX
neratinib	Anticancer drug	***
nicardipine	Calcium channel blocker	***
nifedipine	Calcium channel blocker	***
nilotinib	Anticancer drug	***
ombitasvir/paritaprevir /ritonavir	Hepatitis C direct acting antiviral	***
oxycodone	Narcotic analgesic	***
pethidine	Analgesic	XXX
phenobarbital	Anticonvulsant	XXX
phenytoin	Anticonvulsant	XXX
pimozide	Antipsychotic	XXX
primidone	Anticonvulsant	XXX
propafenone	Antiarrhythmic	XXX
quetiapine	Antipsychotic	***
quinidine	Antiarrhythmic	XXX
ranolazine	Antianginal	XXX
rifabutin	Antimycobacterial	***
rifampin	Antimycobacterial	XXX
rifapentine	Antimycobacterial	***
rimegepant	Migraine medication	***
rivaroxaban	Anticoagulant	***
salmeterol	Long-acting beta-adrenoceptor agonist	***
Sildenafil (when used for erectile dysfunction)	PDE5 inhibitor	***
sildenafil (Revatio®) when used for pulmonary arterial hypertension	PDE5 inhibitor	XXX
silodosin	Benign prostatic hyperplasia agent	XXX
sirolimus	Immunosuppressant	***



Drug	Drug Class	Interaction Code
sofosbuvir/velpatasvir/ voxilaprevir	Hepatitis C direct acting antiviral	***
St. John's Wort (hypericum perforatum)	Herbal product	XXX
suvorexant	Neuropsychiatric agent	***
tacrolimus	Immunosuppressant	***
tadalafil	PDE5 inhibitor	***
tamsulosin	Alpha 1-adrenoreceptor antagonist	***
tezacaftor/ivacaftor	Cystic fibrosis transmembrane conductance regulator potentiator	***
ticagrelor	Cardiovascular agent	***
tolvaptan	Vasopressin receptor antagonist	XXX
trazodone	Antidepressant	***
triamcinolone	Systemic corticosteroid	***
triazolam	Sedative/hypnotic	XXX
ubrogepant	Migraine medication	XXX
ildenafil	PDE5 inhibitor	***
venetoclax	Anticancer drug	***
vinblastine	Anticancer drug	***
vincristine	Anticancer drug	***
voclosporin	Immunosuppressant	XXX
vorapaxar	Cardiovascular agent	***
voriconazole	Antifungal	***
warfarin	Anticoagulant	***

#### Resources:

- PAXLOVID - Fact Sheet for Healthcare Providers: <https://www.fda.gov/media/155050/download>
- Paxlovid Patient Eligibility Screening Checklist for Prescribers (non-pharmacist): <https://www.fda.gov/media/158165/download>
- CDC – Underlying Medical Conditions: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html>
- University of Liverpool COVID-19 Drug Interactions: <https://www.covid19-druginteractions.org/checker>
- NIH COVID-19 Treatment Guidelines: <https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid/>